Compass Therapeutics, Inc.
CMPX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $850 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $850 | $0 | $0 | $0 |
| % Margin | 100% | – | – | – |
| R&D Expenses | $42,342 | $38,120 | $29,997 | $20,337 |
| G&A Expenses | $15,133 | $12,243 | $11,658 | $10,927 |
| SG&A Expenses | $15,133 | $12,243 | $11,658 | $10,927 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $50,618 |
| Operating Expenses | $57,475 | $50,363 | $41,655 | $81,882 |
| Operating Income | -$56,625 | -$50,363 | -$41,655 | -$81,882 |
| % Margin | -6,661.8% | – | – | – |
| Other Income/Exp. Net | $7,250 | $7,869 | $2,430 | -$299 |
| Pre-Tax Income | -$49,375 | -$42,494 | -$39,225 | -$82,181 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$49,375 | -$42,494 | -$39,225 | -$82,181 |
| % Margin | -5,808.8% | – | – | – |
| EPS | -0.36 | -0.33 | -0.35 | -1.31 |
| % Growth | -9.1% | 5.7% | 73.3% | – |
| EPS Diluted | -0.36 | -0.33 | -0.35 | -1.31 |
| Weighted Avg Shares Out | 137,108 | 127,027 | 105,186 | 62,870 |
| Weighted Avg Shares Out Dil | 137,108 | 127,027 | 105,186 | 62,870 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7,300 | $0 | $2,360 | $29 |
| Interest Expense | $0 | $0 | $2,360 | $370 |
| Depreciation & Amortization | $1,753 | $1,890 | $1,904 | $1,624 |
| EBITDA | -$54,872 | -$48,473 | -$39,751 | -$80,187 |
| % Margin | -6,455.5% | – | – | – |